BioAge Labs, Inc.
BioAge Labs, Inc.（BIOA）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · BIOA · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
11
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
BioAge Labs, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
BIOA 季度内部人买卖趋势
BIOA 内幕交易卖出 · BIOA 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
活跃内部人
近12个月交易最活跃 · BIOA CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
BIOA 高管卖出股份 · BIOA 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Apr 23, 2026 | GOLDSTEIN DOV A MD CFO | Option | 3,542 | $16K | Form 4 |
| Apr 1, 2026 | RUBIN PAUL D Chief Medical Officer | Option | 3,383 | $22K | Form 4 |
| Apr 1, 2026 | RUBIN PAUL D Chief Medical Officer | Option | 5,437 | $22K | Form 4 |
| Apr 1, 2026 | RUBIN PAUL D Chief Medical Officer | Sale | 8,820 | $157K | Form 4 |
| Mar 2, 2026 | RUBIN PAUL D Chief Medical Officer | Option | 2,000 | $13K | Form 4 |
| Mar 2, 2026 | RUBIN PAUL D Chief Medical Officer | Option | 5,433 | $22K | Form 4 |
| Mar 2, 2026 | RUBIN PAUL D Chief Medical Officer | Sale | 7,433 | $151K | Form 4 |
| Mar 1, 2026 | GOLDSTEIN DOV A MD CFO | Option | 3,542 | $16K | Form 4 |
| Feb 2, 2026 | RUBIN PAUL D Chief Medical Officer | Option | 2,000 | $13K | Form 4 |
| Feb 2, 2026 | RUBIN PAUL D Chief Medical Officer | Option | 5,433 | $22K | Form 4 |
| Feb 2, 2026 | RUBIN PAUL D Chief Medical Officer | Sale | 7,433 | $139K | Form 4 |
| Feb 1, 2026 | GOLDSTEIN DOV A MD CFO | Option | 3,541 | $16K | Form 4 |
| Jan 16, 2026 | GOLDSTEIN DOV A MD CFO | Option | 3,542 | $16K | Form 4 |
| Jan 13, 2026 | GOLDSTEIN DOV A MD CFO | Option | 27,000 | $227K | Form 4 |
| Jan 13, 2026 | GOLDSTEIN DOV A MD CFO | Sale | 8,974 | $165K | Form 4 |
| Jan 13, 2026 | GOLDSTEIN DOV A MD CFO | Sale | 4,440 | $86K | Form 4 |
| Jan 13, 2026 | GOLDSTEIN DOV A MD CFO | Sale | 11,663 | $240K | Form 4 |
| Jan 13, 2026 | GOLDSTEIN DOV A MD CFO | Sale | 1,923 | $41K | Form 4 |
| Jan 13, 2026 | Fortney Kristen CEO · Director | Sale | 233,107 | $4.22M⚡ | Form 4 |
| Jan 2, 2026 | RUBIN PAUL D Chief Medical Officer | Option | 2,000 | $13K | Form 4 |
| Jan 2, 2026 | RUBIN PAUL D Chief Medical Officer | Option | 5,433 | $22K | Form 4 |
| Jan 2, 2026 | RUBIN PAUL D Chief Medical Officer | Sale | 7,433 | $95K | Form 4 |
| Dec 9, 2025 | RUBIN PAUL D Chief Medical Officer | Option | 18,000 | $118K | Form 4 |
| Dec 9, 2025 | RUBIN PAUL D Chief Medical Officer | Sale | 18,000 | $216K | Form 4 |
| Dec 4, 2025 | RUBIN PAUL D Chief Medical Officer | Option | 68,897 | $283K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 BIOA 内幕交易
BIOA 内幕交易
BioAge Labs, Inc.（BIOA）内幕交易数据来源于公司内部人（包括RUBIN PAUL D (Chief Medical Officer), GOLDSTEIN DOV A MD (CFO), Fortney Kristen (CEO · Director)）提交的SEC Form 4申报文件。过去12个月内，3位内部人向SEC提交了交易申报。BIOA内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看BioAge Labs, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
BIOA 内幕交易 · 5个问题BioAge Labs, Inc.（BIOA）的内部人包括高管和董事，如RUBIN PAUL D (Chief Medical Officer), GOLDSTEIN DOV A MD (CFO), Fortney Kristen (CEO · Director)等。过去12个月内，3位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026